Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal

Zhang, Kai; Jiang, Haifeng; Zhang, Qiaoyang; Du, Jing; Wang, Yuan; Zhao, Min

doi:10.1016/j.comppsych.2015.11.010

Cited by 31 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with methamphetamine literature, the results are inconsistent. Thus, while Angelucci et al (2007) and Zhang et al (2016) observed a significant decrease in serum BDNF levels in patients with history of chronic heroin abuse, in contrast Zhang et al (2014) observed increased levels in heroin-dependent patients during both early withdrawal (1-7 days) and 1 month after heroin cessation compared to healthy controls, a result consistent with those of Heberlein et al (2011) (Angelucci et al, 2007;Zhang et al, 2016, but see also Heberlein et al, 2011;Zhang et al, 2014). They found a positive correlation between peripheral BDNF levels and opiate craving in opiate-dependent patients.…”

Section: A Potential Biomarker?supporting

confidence: 73%

“…Interestingly, as previously observed with methamphetamine, regulation of BDNF may follow a dynamic process. Thus, in their study, Zhang et al (2016) found a lower serum BDNF level in heroin-dependent patients than in healthy patients in the early withdrawal, which increased after 6 months abstinence, but remained still below the levels of healthy controls.…”

Section: A Potential Biomarker?mentioning

confidence: 88%

“…At this time in heroin-dependent patients, there have been four studies measuring levels of serum BDNF (Angelucci et al, 2007;Heberlein et al, 2011;Zhang et al, 2016Zhang et al, , 2014. As with methamphetamine literature, the results are inconsistent.…”

Section: A Potential Biomarker?mentioning

confidence: 89%

See 2 more Smart Citations

BDNF During Withdrawal

Geoffroy¹,

Noble²

2017

Vitamins and Hormones

View full text Add to dashboard Cite

Section: A Potential Biomarker?supporting

confidence: 73%

Section: A Potential Biomarker?mentioning

confidence: 88%

See 1 more Smart Citation

BDNF During Withdrawal

Geoffroy¹,

Noble²

2017

Vitamins and Hormones

View full text Add to dashboard Cite

“…In support of this theory, clinical studies investigating subjective reporting in electronic diaries obtained from heroin addicts identified feeling sad as a driver of opioid craving [30], whereas subjects on buprenorphine or methadone maintenance continued therapy because they want to feel ‘normal’ [31,32]. We have recently argued that the opioid abstinence syndrome and the anxiogenic and negative affective states that evolve following abstinence [25,33] are likely salient factors for learning that opioids relieve negative affect, which drives subsequent addictive behaviors [34 • ]. …”

Section: Hypodopaminergia Driven By Neuroinflammation Is a Shared Phementioning

confidence: 99%

“…Opioid withdrawal elevated BDNF mRNA and protein levels in the VTA [54]. Interestingly, BDNF serum levels were altered in heroin-dependent patients after 26 weeks of abstinence, which correlated with protracted withdrawal symptoms (appearance of anxiety and depressive symptoms) [33]. Similarly, serum BDNF was proposed as a biomarker or determinant of bipolar disorder or depressive symptoms [55,56].…”

Section: Hypodopaminergia Driven By Neuroinflammation Is a Shared Phementioning

confidence: 99%

Neuroinflammation—a co-occurring phenomenon linking chronic pain and opioid dependence

Cahill

Taylor

2017

Current Opinion in Behavioral Sciences

View full text Add to dashboard Cite

Chronic pain is a disease that encompasses both sensory and emotional elements. Opioids are highly effective analgesics because they target both of these elements, by inhibiting pain pathways and alleviating negative affect (including depression) by engaging reward or hedonic pathways. Unfortunately, chronic opioid use is limited by the development of unwanted side effects, such as tolerance, hyperalgesia, and abuse liability. Thus, the challenge of providing effective pain treatment while minimizing these unwanted side effects is an ongoing issue with significant clinical and societal impact. In this review, we posit that neuroinflammation within the central nervous system is a shared phenomenon between chronic pain and opioids that contributes to pain sensitization and negative affect. The implications for pain progression, addiction liability, and alternative treatment strategies are discussed.

show abstract

Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders

Marrero-Cristobal

Gelpi-Dominguez

Morales-Silva

et al. 2021

J of Neuroscience Research

View full text Add to dashboard Cite

Substance use disorder (SUD) is a complex condition that involves the induction of molecular and physiological alterations by the use and abuse of illicit substances. The prevalence of illicit drug use has caused this disorder to grow exponentially over the past 5 years (National Institute of Drug Abuse, 2020). To date, there are several FDA-approved pharmacological treatments for substances that may cause dependency, such as heroin, morphine, alcohol, and nicotine, directed to the attenuation of drug craving, and increase time to relapse. Known as medication-assisted treatment, such FDA-approved pharmaceutical interventions can be used to increase the effectiveness of other substance abuse treatments, including the use of buprenorphine (commonly used in opioid use disorder, OUD).Buprenorphine works as a partial agonist that binds to the opioid receptors in the brain, allowing a partial activation of the receptor when it is activated with opioids, and thus reducing the rewarding effects (James & Williams, 2020). Another FDA-approved treatment for OUD is naloxone, a known opioid receptor antagonist that reduces activation and prevents other endogenous ligands to bind to that receptor (Becker & Chartoff, 2019;James & Williams, 2020). These types of pharmacological treatments are still not available for substances such as cocaine, methamphetamines, or cannabis which limit treatment options. The percentage cocaine users aged

show abstract

Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal

Cited by 31 publications

References 32 publications

BDNF During Withdrawal

BDNF During Withdrawal

Neuroinflammation—a co-occurring phenomenon linking chronic pain and opioid dependence

Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders

Contact Info

Product

Resources

About